Background: Eicosapentaenoic acid is a fish oil fatty acid that has been shown to decrease blood pressure (BP) in humans. The mechanism by which this fatty acid produces this effect is unknown. Angiotensin II increases BP by inducing vasoconstriction of vascular smooth muscle cells, an event that is mediated by an increase of intracellular calcium and an increase of protein kinase C activity. Methods: We determined the effects of eicosapentaenoic acid on angiotensin II-induced calcium signaling, and protein kinase C activity in cultured rat aortic smooth muscle cells. Incorporation of eicosapentaenoic acid into cell phospholipids was determined by gas chromatography/mass spectrometry. Intracellular calcium concentration was determined using fura-2, and protein kinase C activity was assessed by an ELISA assay using a phosphospecific antiserum for protein kinase C substrates. Results: We found that eicosapentaenoic acid was incorporated into cell phospholipids within 20 min. Eicosapentaenoic acid (10 or 25 mol/L) did not alter basal
icosapentaenoic acid (EPA) is one of the dietary n-3 polyunsaturated fatty acids present in fish oils. Many recent studies in both animals and in humans have suggested that dietary EPA can lower blood pressure (BP) and improve cardiovascular health. [1] [2] [3] [4] The mechanism by which EPA lowers BP remains to be elucidated. EPA has been shown to inhibit smooth muscle contraction, 5, 6 which may account for the BP-lowering effect of EPA. Earlier studies have demonstrated that EPA can decrease vasoconstrictor-induced calcium signaling, an event that leads to contraction in vascular smooth muscle cells. 7, 8 The present study was undertaken to investigate the mechanism by which EPA decreases agonist-induced calcium release, and potential effects on protein kinase C (PKC), another important mediator of agonist-induced vascular smooth muscle contraction. We found that EPA decreases the amount of calcium available for release from intracellular stores, and decreases angiotensin II (Ang II)-induced phosphoylation of PKC substrates. Both of these mechanisms can decrease vascular contraction in response to agonists, such as Ang II.
Methods

Materials
All reagents and media were purchased from Sigma Chemical Company (St. Louis, MO), unless noted otherwise. Eicosapentaenoic acid was dissolved in dimethyl-sulfoxide (DMSO), and then diluted to final working concentrations with aqueous solutions. Final concentration of DMSO was Յ0.05% in all studies. Equivalent DMSO vehicle was used as control in all studies.
Preparation of Vascular Smooth Muscle Cells
Male Sprague-Dawley rats (250 to 300 g) were obtained from Bantin and Kingman (Fremont, CA). The animals were housed in a vivarium (approved by the American Association for the Accreditation of Laboratory Animal Care) on a 12-h light/dark cycle, at 24°C with free access to food and chow. Vascular smooth muscle cells (VSMCs) were isolated from the thoracic aorta by enzymatic dispersion as previously reported. 9 The VSMCs were maintained in DME/F12 medium with 10% bovine serum and cells from passage 4 to 12 were used for all experiments. The VSMCs were authenticated using immunohistochemical staining for smooth muscle ␣-actin. Cultures showing Ͼ95% staining for ␣-actin were used.
EPA Incorporation Into VSMC Phospholipids
Confluent VSMC in serum-free medium were treated with 25 mol/L EPA. After a 20-min incubation, cells were washed three times with balance salt solution (BSS) with 0.5% bovine serum albumin (BSA) to remove the unincorporated fatty acids, followed by an additional three times with BSS. Cells were then scraped off incubation dishes, transferred into glass centrifuge tubes, and centrifuged at 200 g for 10 min. The supernatant was then aspirated and the membrane phospholipids extracted using a modification of Hara and Radin. 10 The pellet volume was estimated and 3:2 hexane:2-propanol added at the ratio of 18 mL/g of cells (usually about 0.5 mL). The air in the tube was replaced with argon gas, the cells were freeze fractured, vigorously vortexed, and centrifuged at 200 g for 10 min. The supernatant was transferred to a clean glass tube and dried down to near dryness under a gentle stream of nitrogen for subsequent separation. Methyl esters (ME) of extracted lipids were prepared by transesterification using a Sodium Methoxide MEOH Kit (Alltech Associates, Deerfield IL). Samples were suspended in sodium methoxide/methanol and 1 mL of benzene. The resultant solution was heated to 80°C for 20 min and then allowed to cool to ambient temperature. The cooled mixture was then transferred to a separatory funnel and 3 mL of water and 3 mL of diethyl ether were added. The lower layer was then extracted and removed. The remaining ether layer was then again washed with another 3 mL of water and extracted. The benzene/ether layer was transferred into a glass centrifuge tube and dried over anhydrous sodium sulfate. The EPA methyl ester was purchased from Sigma Chemical Co. Evaluation was conducted on a Hewlett-Packard 6890 series Gas Chromatograph (Wilmington, DE) equipped with a 30-m HP-5MS capillary column using helium as the carrier gas at 1 mL/min with an injection port temperature of 250°C. Runs consisted of an initial oven temperature of 60°C and ramped over 20 min to 280°C. Instrument control, data collection, and data processing were done using Chemstation software integrated with the gas chromatograph/mass spectrometer (Wilmington, DE).
Intracellular Calcium Measurements
The VSMCs were seeded onto 25-mm round glass coverslips and grown to confluence. After overnight serum deprivation, cells were loaded with 4 mol/L fura-2-acetoxymethylester (Molecular Probes, Eugene, OR) for 40 min at 37°C in a HEPES-buffered balanced salt solution, washed and then incubated for an additional 20 min to allow hydrolysis of the entrapped acetylmethyl ester. Intracellular calcium changes were monitored using a Deltascan Spectrofluorometer (Photon Technology International, South Brunswick, NJ) at 510 nm with excitation wavelengths alternating between 340 (F340) and 380 (F380) nm. At the end of each experiment, the minimum (R min ) and maximum (R max ) ratio of F340 and F380 (R340/380) was determined in buffers containing 0 mmol/L Ca 2ϩ plus 2 mmol/L EGTA and 10 mmol/L Ca 2ϩ i , respectively, and the intracellular calcium concentration was then calculated from the resulting data by ratio analysis according to the method of Grynkiewicz et al. 11 All data were individually corrected for autofluorescence by ionic manganese (Mn 2ϩ ) quenching and each coverslip was calibrated separately.
Experimental Protocols
To evaluate the effect of EPA on intracellular calcium response, fura-2-loaded cells were treated with EPA (2.5 to 25 mol/L) for 20 min, and then stimulated with 100 nmol/L Ang II. The change in fluorescence was then recorded for 10 min. Thapsigargin (TG) is a sesquiterpene lactone that is a potent inhibitor of microsomal Ca 2ϩ -ATPase and has been used to evaluate inositol trisphosphate (IP 3 )-sensitive calcium stores without activating IP 3 receptors. 12 We have previously used TG in VSMC in our laboratory. 13 In the studies using TG, VSMC were loaded with fura-2 as described previously, treated with 10 mol/L EPA for 20 min, and then challenged with 1 mol/L TG. Results were recorded as the emission fluorescence ratios of 340/380 excitation.
Cation Influx Measurements
The Ang II-induced calcium influx was estimated by using the fura-2 quenching characteristics of Mn 2ϩ . 13, 14 MnCl 2 (250 mol/L) as a surrogate for calcium was added 30 sec before the addition of 100 nmol/L Ang II. Total fluorescence at 360 nm (Fl 360, the isosbestic point for fura-2) was collected for 2 min after Ang II addition. The quench rate (⌬Fl 360 /⌬T) was determined by dividing the decrease in fluorescence by the time period.
Ang II-Binding Assays
To assess possible effects of EPA on Ang II binding in VSMCs, cells grown in 12-well plates were grown to confluence and deprived of serum for 24 h. The cells were then washed twice in tris-buffered saline (TBS), and incubated with 1 to 100 mol/L EPA in TBS for 30 min at 37°C. The cells were then washed twice with TBS at room temperature, then cooled to 4°C. After cooling, the plates were then washed three times with cold TBS, and incubated with TBS containing 1% BSA and 0.1 Ci of 125 I-angiotensin II (1-sar, 8-ileu) antagonist (DuPont NEN, Boston, MA). After a 2-h incubation at 4°C, the cells were washed with cold TBS and lysed with 1 mL of 1 N NaOH. Cell lysates were analyzed for 125 I using a gamma counter (1277 Gammamaster, LKB, Gaithersburg, MD). Protein concentration of the cell lysates was determined using the bicinchoninic acid method described previously.
PKC Activity Assays
The PKC activity was assessed by detecting phosphorylated PKC substrates using an ELISA method developed in our laboratory. The VSMCs were grown in 100-mm diameter dishes until confluent, then serum-deprived for 24 h. Cells were washed three times with HPSS, then exposed to EPA (10 mol/L), Ang II (100 nmol/L), or Ang II ϩ EPA in HPSS for 30 min at 37°C. The cells were washed twice with ice-cold phosphate-buffered saline (PBS), and then lysed with lysis buffer containing 150 mmol/L NaCl, 10 mmol/L Tris-HCl (pH 7.4), 1% NP-40, 0.1% sodium dodecyl sulfate (SDS), 1 mmol/L EDTA, 0.1% sodium deoxycholate, and 1 mmol/L sodium orthovanadate. Lysates were centrifuged at 12,000 g at 4°C. Protein content of the lysates was determined using the BCA method described previously. One to 10 g of protein in PBS was added to each well of a 96-well microplate and allowed to incubate overnight at room temperature. The wells were washed three times with PBS ϩ 0.05% Tween 20 (PBST), then incubated with blocking buffer (PBST ϩ 10 mg/mL BSA) for 60 min at 37°C. Then the wells were washed four times with PBST. A phosphospecific PKC substrate antibody (Phospho-(ser) PKC substrate antibody; Cell Signaling Technology, Beverly, MA) was added to each well and incubated overnight at 4°C. This antibody detects phosphorylated serine residues surrounded by arginine or lysine at the Ϫ3, Ϫ2, and ϩ3 positions and a hydrophobic residue at the ϩ1 position. After washing four times; with PBST, an alkaline phosphatase secondary antibody (Cell Signaling Technology) was incubated with the samples for 1 h at 37°C. After washing with PBST, "1-step PNPP" (Pierce Chemicals, Rockford, IL) was added to each well and incubation was carried out for 3 h at 37°C. Absorbance at 405 nm was read with a Dynatech plate reader (Dynatech Laboratories Inc, Chantilly, VA) as described previously.
Statistics
All values shown are mean values Ϯ SEM. Significant differences were tested by either t tests or ANOVA. A P Ͻ .05 was considered significant.
Results
Incorporation of EPA Into Cell Phospholipids
Lipid extracts from cells treated with EPA were isolated as described previously and the resulting methyl esters evaluated by GC/MS. Methyl ester EPA was also evaluated for comparison. As shown in Fig. 1 , the extract from the EPA-treated cells was very similar to that of the ME-EPA standard, demonstrating incorporation of EPA into the cell phospholipids.
Effect of EPA on Intracellular Calcium
The EPA decreased the calcium response to Ang II in a dose-dependent fashion, but had no effect on basal [Ca 2ϩ ] i (Fig. 2) . Because 10 mol/L EPA showed a maximal inhibition of the calcium response, this concentration of EPA was used in further studies. A typical time course to the showing the effects of 10 mol/L EPA on the [Ca 2ϩ ] i response to 100 nmol/L Ang II is shown in Fig. 3 . Time courses with other concentrations of EPA were similar.
The amount of calcium mobilized by TG was also significantly inhibited by 10 and 25 mol/L EPA (Fig. 4) , suggesting that EPA decreases the amount of calcium releasable from the sarcoplasmic reticulum. EPA at a concentration of 10, but not 5 mol/L, inhibited Ang II-induced cation influx as determined by the manganese influx method. The influx rate (⌬Fl 360 /⌬T) in control VSMC was 0.0391 Ϯ 0.0091, and 0.0290 Ϯ 0.0071 for VSMCs treated with 10 mol/L EPA (P Ͻ .05, n ϭ 15 for each group).
Effect of EPA on Ang II Binding
There was no significant inhibition of Ang II binding to VSMC exposed to 1 to 25 mol/L EPA (Fig. 5) . However, concentrations of EPA more than 25 mol/L reduced the amount of Ang II binding to VSMC.
Effect of EPA on PKC Activity
The EPA inhibited PKC activity as determined by the ELISA method for phosphorylated substrates of PKC. EPA alone at 10 or 25 mol/L had no effect on phosphorylation of PKC substrates, whereas Ang II (100 nmol/L) increased the amount of immunoreactivity detected with this antibody. Pretreatment of VSMC with 10 or 25 mol/L EPA inhibited this Ang II-stimulated increase (Fig. 6 ).
Discussion
We found that acute exposure of VSMC to EPA could dramatically alter the calcium signaling in response to Ang II. In our studies, EPA was incorporated into cultured VSMCs within this time period. Other studies have shown that EPA is incorporated into the sn-2 position of membrane phospholipids of VSMC. 15 This incorporation into the phospholipid pool results in altered signaling in response to agonists, such as Ang II.
We also found that PKC activity is decreased by acute exposure to this omega-3 fatty acid. Because both [Ca 2ϩ ] i and PKC are important signaling pathways for smooth muscle contraction by a number of vasoconstrictors, including Ang II, these results show that EPA can inhibit this process at a cellular level. In addition, our results show that relatively low concentrations of EPA, 10 to 30 mol/L, are effective in reducing this signaling. Other studies have shown that acute (10 to 20 min) exposure to similar concentrations EPA (5 to 30 mol/L) could inhibit agonist-induced calcium release and VSMC 8 and relax contracted aortas from hypertensive rats. 7 The failure of 10 mol/L EPA to inhibit binding of Ang II to VSMC demonstrates that the observed decrease of calcium response to Ang II is not due to impaired binding of Ang II. Based on our results, this could become a factor at higher concentrations of EPA (50 mol/L). Previous studies using membranes from VSMC have suggested that 10 mol/L EPA could inhibit Ang II binding. 16 However, based on the results of our studies, this does not appear to be the case in intact VSMCs. Thus, reductions of the Ang II-induced [Ca 2ϩ ] i response by EPA must be due to a postreceptor mechanism.
The mechanism by which EPA decreases the [Ca 2ϩ ] i response to Ang II appears to be, in part, due to an impaired release of calcium from TG-sensitive stores. Among these reservoirs of calcium is the sarcoplasmic reticulum. Thus, our results suggest that EPA either decreases the amount of calcium available for release from the sarcoplasmic reticulum or inhibits the release of calcium from the sarcoplasmic reticulum. Ang II stimulates the release of IP 3 , which then binds to receptors on the sarcoplasmic reticulum, thereby stimulating the release of calcium into the cytoplasm. 16 Other studies have shown that EPA causes a slow, transient increase of [Ca 2ϩ ] i in VSMCs from hypertensive rats, 7 suggesting that EPA can decrease the amount of calcium available for release by Ang II or TG. In this regard, EPA has also been shown to release calcium from the IP 3 -sensitive pool in JURKAT cells. 17 We did not observe any increase of basal [Ca 2ϩ ] i with EPA in the present studies and there was no difference of basal (prestimulation) [Ca 2ϩ ] i between EPAtreated and control VSMCs. In other studies, EPA has also been shown to decrease sarcoplasmic reticulum function in isolated ventricular myocytes. 18, 19 In these studies, the results suggested that there was both a reduced availability of calcium and inhibition of calcium release caused by EPA. In combination with previous studies, the results of the present studies indicate that EPA reduces the amount of calcium released from IP 3 -sensitve stores in the sarcoplasmic reticulum in response to Ang II.
FIG. 1. Graphs of GC/MS
Our results using manganese influx as an indicator of cation influx, demonstrate that 10 mol/L EPA can inhibit the Ang II-stimulated influx of divalent cations. These 
FIG. 4.
Combined results of experiments using thapsigargin to release Ca 2ϩ from the sarcoplasmic reticulum. Control-treated vascular smooth muscle cells (VSMCs) showed a more than 170% increase of intracellular calcium when treated with 1 mol/L thapsigargin. In VSMCs preincubated with 10 and 25 mol/L eicosapentaenoic acid (EPA 10 and EPA 25, respectively), the response to thapsigargin was significantly less than in the control group (n ϭ 12 for each group). results are in agreement with earlier patch-clamp studies that have shown that EPA can inhibit vasopressin-induced Ca 2ϩ influx in VSMCs. 8 Thus, it can be implied from our results and those of other investigators, that EPA can inhibit both the Ang II-stimulated release of calcium from the sarcoplasmic reticulum and the influx of calcium from extracellular sources. This twofold mechanism would prevent the sarcoplasmic reticulum from being refilled after release of stored calcium.
Protein kinase C is an important mediator of smooth muscle contraction that is increased by Ang II-induced stimulation of phospholipase C. 20 Although the results of the present study do not allow for identification of specific substrates that were phosphorylated by PKC in these studies, they do allow us to assess the general activity of PKC. In VSMC, PKC can be stimulated by the production of diacylglycerol produced by phospholipase C, or by an increase of [Ca 2ϩ ] i . 20 Our results do not allow us to differentiate between these two possible sources of stimulation. However, it is apparent that EPA reduced Ang II-stimulated increases of [Ca 2ϩ ] i substantially in our studies. This reduction in [Ca 2ϩ ] i may be the cause of reduced PKC activity in the EPA-treated VSMC. However, other researchers have shown that EPA can reduce diacylglycerol production in rat mesenteric VSMC 15 and in bovine aortic endothelial cells. 21 EPA has also been shown to decrease PKC activity in coronary artery smooth muscle cells 22 and in porcine cardiac myocytes. 23 This decrease in PKC may be the mechanism by which EPA inhibits arterial contraction. 6, 7 EPA has also been shown to inhibit VSMC proliferation induced by serotonin, 24 vasopressin, 8 thromboxane A2, 25 and in VSMC from spontaneously hypertensive rats. 26 PKC has been shown to be a mediator for VSMC proliferation, 27 potentially by its interaction with mitogen-activated protein (MAP) kinase. 28 It has been shown that EPA modulates MAP kinase signaling through a PKC-dependent mechanism in human T cells. 29 Our results suggest that EPA inhibits VSMC proliferation by decreasing PKC's phosphorylation of some of its substrate proteins. In summary, our results demonstrate the EPA incorporation into VSMC is associated with inhibition of Ang II-stimulated release of calcium from the sarcoplasmic reticulum, either by inhibiting this release or decreasing the amount of stored calcium in the sarcoplasmic reticulum. We also confirmed results that suggest that EPA can inhibit calcium influx. Also, we found that EPA decreases Ang II stimulation of PKC. Both of these signals, [Ca 2ϩ ] i and PKC, are important mediators of smooth muscle contraction in response to Ang II. The inhibition of these mediators by EPA may be the mechanism by which EPA can lower BP and improve cardiovascular health.
FIG. 6.
The effect of eicosapentaenoic acid (EPA) on angiotensin II (Ang II)-stimulated phosphorylation of protein kinase C (PKC) substrates. The amount of phosphorylated PKC substrate was measured by ELISA. EPA alone (10 and 25 mol/L) had no effect on PKC substrate phosphorylation. Ang II (100 nmol/L) significantly increased the amount of phosphorylated PKC substrates. Addition of 10 or 25 mol/L EPA prevented this Ang II-induced increase (n ϭ 5 in each group).
